Glossary

clinical cut-off (CCO) – a test result that is associated with an impact on clinical care. With resistance tests a lower CCO is the level below which a drug is still sensitive or active. This is often set at a 20% loss of activity (compared to wild-type HIV). An upper CCO is the level above which the drug is not considered active (ie resistant). This is often set at an 80% loss of activity (compared to wild-type HIV).

Hickman line – a fixed central line that is used to deliver IV drugs close to where they are needed in the body.

symptom – a sign of illness.

SVR (sustained virological response) – having a negative HCV viral load test 6 months after stopping HCV treatment. The response, 6 months after treatment is stopped, determines whether treatment has been effective in terms of clearing HCV. SVR is the most important result from an HCV treatment trial. See ETR.

expanded access programme (EAP) – a scheme that allows people to access a drug before it has been approved (but when approval is expected).

EAPs are for people urgently need treatment as a life-saving option and who do o have the time to wait for the six months that it takes for approval to be finalised. EAPs are usually available for most HIV drugs after the main studies (phase 3) have been completed.

They were an important early result of community activism. They are also called ‘early access’ or ‘named-patient’ programmes.